ZSCAN1 Autoantibodies Are Associated with Pediatric Paraneoplastic ROHHAD.

"all studies were negative (negative data pertaining to immunohistochemistry using rodent based approaches available on dryad).; to test for hypothalamic expression of zscan1 mass spectrometry analysis was performed using immunoprecipitation from human hypothalamic lysates using commercial antibodies to zscan1 zscan1 peptides were readily detectable consistent with protein expression in this tissue (data available on dryad repository).; data availability original data contributing to the main findings in our study as well as additional supplementary figures and tables are provided on dryad repository (temporary link for review: https://datadryad org/stash/share/p0zu0sm4oth44f35oirk6pjhbfjicgghdsbyacc2jwm ). data availability original data contributing to the main findings in our study as well as additional supplementary figures and tables are provided on dryad"

"Conflicts of Interest Nothing to report."

"This research was supported by ROHHAD Fight, Inc, the Shore Foundation, the OMS Life Foundation, the Repository Core for Neurological Disorders, Department of Neurology, Boston Children's Hospital, and the IDDRC (NIH P30HD018655) and NIH R01MH122471. We also acknowledge the New York Blood Center for contribution of healthy control plasma. Instituto Carlos III (ISCIII, PI20/00197 [JD]), and “La Caixa” Foundation (JD). C.M.A. is supported by NIDDK (K23DK120899). Acknowledge the UCSF Nikon Core Facility for microscope imaging equipment and guidance. J.D.L. is funded by a grant from Chan Zuckerberg Biohub. J.D.L., M.R.W., S.J.P., and C.M.B. are funded by the National Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471‐01). S.J.P. and B.T. are also funded by the Brain Research Foundation (Scientific Innovations Award). C.M.B. is also funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (award 1K99NS117800‐01). S.E.V. is funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915‐01)."